TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: reduced levels of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Cmax OXY concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean in vitro OXY skin absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower body fat loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical safety
Endpoint domain: Adverse events/effects
Primary endpoint: Mean HbA1c decrease from baseline to month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Annualised rates of confirmed or severe hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative number of hypoglycaemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of clinical pregnancy per cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: incidence of cerebrovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Physical component summary of the SF-36
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: KOS total score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage fat lost
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rise in RMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gross motor development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSEs detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ETIs detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of alarms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores of factual knowledge of genetics
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: posttreatment symptom improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: corrected visual acuity of 6/18 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: secondary procedures or other complications
Endpoint domain: Adverse events/effects
Primary endpoint: mean daily pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of abdominal pain occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds of being circumcised
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation rates of pharmacies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of time from initial contact to consent
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: median wet-lab capsulorhexis overall performance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving > or =12% increase in FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cost-effectiveness ratio per successfully treated patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Serum osteocalcin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cortisol responses during LDAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Significant retrosternal pain
Endpoint domain: Adverse events/effects
Primary endpoint: Days of pericardial catheterization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: risk of stroke/systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: risk of intracranial hemorrhage
Endpoint domain: Mortality/survival
Primary endpoint: risk of all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: incidence of self-reported urinary tract stones
Endpoint domain: Adverse events/effects
Primary endpoint: Colon-specificity of coated tablets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration of cognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bacteriologic cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Likelihood of using Health Records on iPhone
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean reduction in ADAS-cog score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median pain score on the VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of norepinephrine appearance into the vascular compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of norepinephrine release into the extravascular compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Norepinephrine kinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Emotion regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Deep Vein Thrombosis (DVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: mRNA expression of proinflammatory factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean radiofrequency delivery duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean variation of propionic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Abundance of inflammatory cytokines (VEGF, MCP‐1, IL‐17, IP‐10, IL‐12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T50 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic Rate (MR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Supraclavicular BAT volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: School function improvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Total function scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Knee extension force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Central activation ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neutralizing cross-clade immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rates for clade 2.2 and clade 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Injection-site reactions (pain)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of diabetes mellitus (DM)
Endpoint domain: Mortality/survival
Primary endpoint: TIMI grade 3 flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite of death, recurrent myocardial infarction, cardiogenic shock or congestive heart failure, revascularization and recurrent ischemia at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Very low-density lipoprotein particles (VLDLP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total high-density lipoprotein particles (T-HDLP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Growth hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximal increase in forearm blood flow (FBF) in response to acetylcholine (Ach)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resting forearm blood flow (FBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Performance of the new mechanical puncture echoendoscope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Levels of psychopathology in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flexion strength in the operated leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Extension strength in the operated leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Return to preinjury Tegner level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: cTnT levels after the race
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean score of pain/discomfort (visual analog score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean graft take
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of fixation procedure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Visit-to-visit BP variability (systolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: complete lack of leakage or reduced number of leakage episodes by >50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in snoring intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores in masticatory type
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate tone of lower lip and adequate tongue mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cycle duration and number of cycles in chewing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GOOSS score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median time to recurrent DO (RDO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of recurrent DO (RDO)
Endpoint domain: Adverse events/effects
Primary endpoint: Regular mammography behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythrocyte Superoxide Dismutase Activity (SOD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of organ failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of postmenopausal complaints
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mite survival probabilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SUV decrease 14 days after therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first appropriate ICD therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: weekly UUI episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional support availability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Life contentment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IMx CORE-M index value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erosion rates
Endpoint domain: Adverse events/effects
Primary endpoint: Incident dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Age at peak velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tinnitus severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum PINP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in serum ICTP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in serum NTx concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Procedural ST depression episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CRC-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Rate of reported adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Normative R2* values in the liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normative R2* values in the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pH values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: times spent at and above pH 3.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in NSSI urges and acts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: selection accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive response to surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant decrease in migraine frequency, duration, and intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of dual-wavelength laser treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glycosylated hemoglobin in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: insulin resistance value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prophylactic vancomycin use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pulmonary artery occlusion pressure improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subjective symptoms improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Initial small intestinal glucose absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall small intestinal glucose absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall blood glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: manual muscle test 8 (MMT-8) alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: soluble IL-2RA changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apolipoprotein B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: LDL/ApoB ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cardio-respiratory fitness improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body composition modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cholesterol concentrations increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CT findings of ground-glass attenuation and consolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Average bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage reduction in LV end-systolic volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mortality prediction
Endpoint domain: Mortality/survival
Primary endpoint: Achievement of optimal risk-factor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HbA1c from baseline to six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nitroglycerine usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHO functional class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alphaLF-index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictability of difficult intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Documentation of communication from MHP to PCP
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Timely communication within seven days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acknowledgment of medications in PCP record
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Development of new cancer (all types)
Endpoint domain: Mortality/survival
Primary endpoint: Development of colon cancer
Endpoint domain: Mortality/survival
Primary endpoint: Magnitude of ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraindividual variability of ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional scores (Karlsson‐Peterson and Tegner activity level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant postoperative hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red blood cell transfusion requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfusion of fresh-frozen plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of intimate partner violence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 30-day death or cardiovascular/renal hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: global symptom distress index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-centeredness ratio
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Control of seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Time to seizure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of severe exacerbations per patient per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BBT improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COPM-Performance improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: intention to engage in shared decision making (SDM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Risk of developing T2DM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rates of symptomatic mania remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time taken to symptomatic remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse drug events
Endpoint domain: Adverse events/effects
Primary endpoint: Concentrations of fasting triacylglycerol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentrations of small dense LDL particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clearance of S(+)‐ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained tardive dyskinesia improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term safety and tolerability of valbenazine
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal Voluntary Contraction (MVC) increase in trained FDI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Corticospinal excitability increase in iM1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Interhemispheric inhibition decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: VAS scores during positioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve spinal anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functionality (Barthel Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of iron deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Levels of Hb (Hemoglobin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mortality rate during hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Scores on the Hamilton scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on the Beck Depression Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GlycA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LP-IR levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes